LIPITOR has been studied in more than 400 ongoing and completed studies.

Research on LIPITOR

As the #1 prescribed cholesterol-lowering medication in the world, over 26 million people in the United States have been prescribed LIPITOR.1

LIPITOR has been studied in more than 400 ongoing and completed studies. These studies include over 80,000 patients.2

  • A landmark study found that LIPITOR reduced the risk of heart attack, stroke, certain kinds of heart surgeries, and chest pain in patients with several common risk factors for heart disease*
  • Another landmark study found that LIPITOR significantly reduces the risk of heart attack and stroke in patients with both type 2 diabetes and at least 1 other risk factor for heart disease

Three times more cardiologists surveyed would recommend LIPITOR to their own family members over other cholesterol-lowering medications

Ask your doctor today if LIPITOR is right for you.

*Risk factors include family history, high blood pressure, age, low HDL ("good" cholesterol), or smoking.
†Other risk factors include eye problem, kidney problem, smoking, or high blood pressure.
‡Based on a response from 57 cardiologists in a Harris Interactive Survey of 489 physicians, sampled from the American Medical Association master file, conducted from April 2007-June 2007.

References:

  1. IMS Health. IMS National Prescription Audit Plus. March 2006.
  2. Data on file. Pfizer Inc, New York, NY.
Sign Up Now for the LIPITOR 30-Day Free TrialGet help achieving your cholesterol goals. Join My HeartWise™